<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Low Vision and Vision Rehabilitation in Glaucoma - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAVjVVa8vRJ2d@c3ELTeeAAAAAU","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Low_Vision_and_Vision_Rehabilitation_in_Glaucoma","wgTitle":"Low Vision and Vision Rehabilitation in Glaucoma","wgCurRevisionId":87680,"wgRevisionId":87680,"wgArticleId":5248,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles","Glaucoma"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Low_Vision_and_Vision_Rehabilitation_in_Glaucoma","wgRelevantArticleId":5248,"wgIsProbablyEditable":!1,"wgRelevantPageIsProbablyEditable":
!1,"wgRestrictionEdit":[],"wgRestrictionMove":[],"sdgDownArrowImage":"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr",
"pageVariantFallbacks":"en"},"srfFilteredConfig":null,"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eyeWiki","ext.eyeWiki.slideshow","sentry.init",
"ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Glaucoma is an optic neuropathy characterized by elevated intraocular pressure leading to visual field loss. It is the leading cause of irreversible blindness globally &amp;#91;1&amp;#93;.  Visual impairment experienced by glaucoma patients can result in challenges with activities of daily living (ADLs), increased morbidity, and consequent negative impacts on mental health.&amp;#91;2&amp;#93;&amp;#91;3&amp;#93;&amp;#91;4&amp;#93;&amp;#91;5&amp;#93;&amp;#91;6&amp;#93;&amp;#91;7&amp;#93;  While disease progression is targeted with medicine and surgery, irreversible vision related disabilities can be addressed through low-vision services (LVS).&amp;#91;8&amp;#93;  This article presents information on how to recognize and respond to glaucoma patients with low-vision needs."/>
<meta name="date" content="2022-12-24"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Low Vision and Vision Rehabilitation in Glaucoma" href="/w/index.php?title=Special:ExportRDF/Low_Vision_and_Vision_Rehabilitation_in_Glaucoma&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Low_Vision_and_Vision_Rehabilitation_in_Glaucoma rootpage-Low_Vision_and_Vision_Rehabilitation_in_Glaucoma layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Low+Vision+and+Vision+Rehabilitation+in+Glaucoma" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Low+Vision+and+Vision+Rehabilitation+in+Glaucoma" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbpzyslrbi"></button>
					<div class="collapse navbar-collapse hbpzyslrbi" id="hbpzyslrbi">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Low_Vision_and_Vision_Rehabilitation_in_Glaucoma" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk" class="new"><a href="/w/index.php?title=Talk:Low_Vision_and_Vision_Rehabilitation_in_Glaucoma&amp;action=edit&amp;redlink=1" rel="discussion" title="Discussion about the content page (page does not exist) [t]" accesskey="t" class="new ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Low_Vision_and_Vision_Rehabilitation_in_Glaucoma&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Low_Vision_and_Vision_Rehabilitation_in_Glaucoma&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Low_Vision_and_Vision_Rehabilitation_in_Glaucoma&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Low_Vision_and_Vision_Rehabilitation_in_Glaucoma#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Low Vision and Vision Rehabilitation in Glaucoma</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:Mona.A.Kaleem" title="User:Mona.A.Kaleem">Mona A. Kaleem, MD</a>,&#8201;<a href="/User:Sara.Francomacaro" title="User:Sara.Francomacaro">Sara Francomacaro</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a>,&#160;<a href="/User:Mona.Kaleem" title="User:Mona.Kaleem">Mona Kaleem, MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Up to Date</b>
</div>
</div>&#160;by <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a> on December 25, 2022.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Low_Vision_and_Vision_Rehabilitation_in_Glaucoma&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Low_Vision_and_Vision_Rehabilitation_in_Glaucoma&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table></div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<div class="infobox vertical">
<div class="info-section vertical" style="margin-bottom: 10px;">
<div class="info-section-header">Low Vision
  </div>
<div class="info-section-body">
  </div>
</div>
<div class="info-section horizontal" style="margin-bottom: 10px;">
<div class="info-section-header"><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Diseases_Database">DiseasesDB</a>
        </div>
<div class="info-section-body"><a rel="nofollow" class="external text" href="http://www.diseasesdatabase.com/ddb28256.htm">28256</a>
        </div>
</div>
<div class="info-section horizontal" style="margin-bottom: 10px;">
<div class="info-section-header"><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems">ICD</a>-<a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/ICD-10">10</a>
        </div>
<div class="info-section-body"><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/ICD-10_Chapter_VII:_Diseases_of_the_eye,_adnexa">H</a><a rel="nofollow" class="external text" href="http://apps.who.int/classifications/icd10/browse/2010/en#/H54.2">54.2</a>,<a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/ICD-10_Chapter_VII:_Diseases_of_the_eye,_adnexa">H</a><a rel="nofollow" class="external text" href="http://apps.who.int/classifications/icd10/browse/2010/en#/H54.1">54.1</a>
        </div>
</div>
<div class="info-section horizontal" style="margin-bottom: 10px;">
<div class="info-section-header"><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Medical_Subject_Headings">MeSH</a>
        </div>
<div class="info-section-body"><a rel="nofollow" class="external text" href="https://meshb.nlm.nih.gov/record/ui?ui=D015354">D015354</a>
        </div>
</div>
</div>
<p><br />
</p><p><br />
Glaucoma is an optic neuropathy characterized by elevated intraocular pressure leading to visual field loss. It is the leading cause of irreversible blindness globally <sup id="cite_ref-tham1_1-0" class="reference"><a href="#cite_note-tham1-1">&#91;1&#93;</a></sup>.  Visual impairment experienced by glaucoma patients can result in challenges with activities of daily living (ADLs), increased morbidity, and consequent negative impacts on mental health.<sup id="cite_ref-cesareo2_2-0" class="reference"><a href="#cite_note-cesareo2-2">&#91;2&#93;</a></sup><sup id="cite_ref-medeiros3_3-0" class="reference"><a href="#cite_note-medeiros3-3">&#91;3&#93;</a></sup><sup id="cite_ref-mills4_4-0" class="reference"><a href="#cite_note-mills4-4">&#91;4&#93;</a></sup><sup id="cite_ref-pabon5_5-0" class="reference"><a href="#cite_note-pabon5-5">&#91;5&#93;</a></sup><sup id="cite_ref-ramulu6_6-0" class="reference"><a href="#cite_note-ramulu6-6">&#91;6&#93;</a></sup><sup id="cite_ref-robison7_7-0" class="reference"><a href="#cite_note-robison7-7">&#91;7&#93;</a></sup>  While disease progression is targeted with medicine and surgery, irreversible vision related disabilities can be addressed through low-vision services (LVS).<sup id="cite_ref-renieri8_8-0" class="reference"><a href="#cite_note-renieri8-8">&#91;8&#93;</a></sup>  This article presents information on how to recognize and respond to glaucoma patients with low-vision needs. 
</p>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Definition_of_Low_Vision"><span class="tocnumber">1</span> <span class="toctext">Definition of Low Vision</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Glaucoma_and_Low_Vision_Epidemiology"><span class="tocnumber">2</span> <span class="toctext">Glaucoma and Low Vision Epidemiology</span></a></li>
<li class="toclevel-1 tocsection-3"><a href="#Vision_Impairment_and_Disability"><span class="tocnumber">3</span> <span class="toctext">Vision Impairment and Disability</span></a></li>
<li class="toclevel-1 tocsection-4"><a href="#Evaluation_of_Low_Vision_in_Glaucoma"><span class="tocnumber">4</span> <span class="toctext">Evaluation of Low Vision in Glaucoma</span></a>
<ul>
<li class="toclevel-2 tocsection-5"><a href="#History"><span class="tocnumber">4.1</span> <span class="toctext">History</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#Visual_Acuity"><span class="tocnumber">4.2</span> <span class="toctext">Visual Acuity</span></a></li>
<li class="toclevel-2 tocsection-7"><a href="#Near_Acuities"><span class="tocnumber">4.3</span> <span class="toctext">Near Acuities</span></a></li>
<li class="toclevel-2 tocsection-8"><a href="#Visual_Field"><span class="tocnumber">4.4</span> <span class="toctext">Visual Field</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#Contrast_Sensitivity"><span class="tocnumber">4.5</span> <span class="toctext">Contrast Sensitivity</span></a></li>
<li class="toclevel-2 tocsection-10"><a href="#Observation_of_Patient"><span class="tocnumber">4.6</span> <span class="toctext">Observation of Patient</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-11"><a href="#Management_of_Glaucoma_Patients_with_Low_Vision"><span class="tocnumber">5</span> <span class="toctext">Management of Glaucoma Patients with Low Vision</span></a>
<ul>
<li class="toclevel-2 tocsection-12"><a href="#Near_magnification.5B7.5D"><span class="tocnumber">5.1</span> <span class="toctext">Near magnification<sup>&#91;7&#93;</sup></span></a></li>
<li class="toclevel-2 tocsection-13"><a href="#Field_Enhancement"><span class="tocnumber">5.2</span> <span class="toctext">Field Enhancement</span></a></li>
<li class="toclevel-2 tocsection-14"><a href="#Glare_control"><span class="tocnumber">5.3</span> <span class="toctext">Glare control</span></a></li>
<li class="toclevel-2 tocsection-15"><a href="#ADL_Assistance"><span class="tocnumber">5.4</span> <span class="toctext">ADL Assistance</span></a></li>
<li class="toclevel-2 tocsection-16"><a href="#Mental_Health_Impairments"><span class="tocnumber">5.5</span> <span class="toctext">Mental Health Impairments</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-17"><a href="#Treatment_Outcomes"><span class="tocnumber">6</span> <span class="toctext">Treatment Outcomes</span></a></li>
<li class="toclevel-1 tocsection-18"><a href="#Additional_Resources"><span class="tocnumber">7</span> <span class="toctext">Additional Resources</span></a></li>
<li class="toclevel-1 tocsection-19"><a href="#References"><span class="tocnumber">8</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h1><span class="mw-headline" id="Definition_of_Low_Vision">Definition of Low Vision</span></h1>
<p>According to the American Academy of Ophthalmology’s Preferred Practice Patterns (PPP) for Vision Rehabilitation, low vision is defined as a visual impairment caused by eye disease in which visual acuity is 20/50 or worse in the better-seeing eye and cannot be corrected or improved with regular eyeglasses, contact lenses, medicine, or surgery.<sup id="cite_ref-american9_9-0" class="reference"><a href="#cite_note-american9-9">&#91;9&#93;</a></sup>  It is further qualified as uncorrectable vision loss that may be better than 20/50 acuity, but which involves loss of visual field, reduced contrast sensitivity, increased glare, or difficulty with daily activities. 
</p><p>The International Classification of Diseases, Ninth Revision (ICD-9) and the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10 CM) define low vision as patients who fall within Category of Visual Impairment 1 or 2, which includes patients with visual acuity 20/70 or worse in the better-seeing eye, or with any loss in visual field that impacts ADLs. 
</p>
<h1><span class="mw-headline" id="Glaucoma_and_Low_Vision_Epidemiology">Glaucoma and Low Vision Epidemiology</span></h1>
<p>An understanding of the epidemiology of glaucoma patients with low vision is limited to prevalence figures estimated through combined meta-analyses and census data ranging from 2010 to 2015.  It is also limited by the way in which terms are defined, with glaucoma definitions varying by visual field testing or intraocular pressure measurements, and low vision being defined through the limited scope of visual acuity, which is often not the primary complaint in glaucoma.  
</p><p>In 2013, the number of people (40-80 years of age) worldwide with glaucoma was estimated at 64.3 million, projected to include 76.0 million by 2020 and 111.8 million by 2040.<sup id="cite_ref-tham1_1-1" class="reference"><a href="#cite_note-tham1-1">&#91;1&#93;</a></sup>  The most up-to-date estimates for the United States indicate that there are 2.7 million Americans with glaucoma3, (1.9% of the population).  Low vision (when defined as visual acuity 20/50 or worse in the better-seeing eye) was last estimated in 2010 to affect 2.9 million people in the United States (2.04% of the population).<sup id="cite_ref-massof10_10-0" class="reference"><a href="#cite_note-massof10-10">&#91;10&#93;</a></sup>
</p><p>From a few studies defining symptomatic complaints in glaucoma, there is some understanding of the overlap of low vision in glaucoma patients.  For example, a small survey study found that 57% of glaucoma patients reported needing more light, 55% reported blurry vision, 46% reported glare, 36% reported noticeable visual field losses, and 30% reported contrast sensitivity losses.<sup id="cite_ref-hu11_11-0" class="reference"><a href="#cite_note-hu11-11">&#91;11&#93;</a></sup>  Glare, visual field losses, and contrast sensitivity losses would directly qualify patients as having low vision as defined by the Academy’s PPP, and as such are visual disabilities targetable by LVS.  There are a significant number of people affected by glaucoma, and, of those patients, many are symptomatic in ways that meet the criteria for low vision. A cross-sectional study describing demographic and clinical characteristics of a glaucoma patient population attending vision rehabilitation found that patients reported the greatest difficulty with reading (88%), writing (72%), adn mobility (67%).  Most glaucoma patients attending low vision rehabilitation were functionally monocular, but not legally blind.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12">&#91;12&#93;</a></sup>    
</p>
<h1><span class="mw-headline" id="Vision_Impairment_and_Disability">Vision Impairment and Disability</span></h1>
<p>The loss of peripheral vision as detected by visual field testing is the most commonly followed measurement of glaucoma progression. The severity, magnitude, and rates of change in binocular visual field sensitivity are significantly correlated with quality-of-life measures in glaucoma patients, especially in later disease.<sup id="cite_ref-medeiros3_3-1" class="reference"><a href="#cite_note-medeiros3-3">&#91;3&#93;</a></sup>  However, patients can experience a decline in quality of life and increase in disability even in early stages of glaucoma, and these changes may not always correlate with clinical measures. 
</p><p>The Collaborative Initial Glaucoma Treatment Study (CIGTS), found that more than 25% of newly diagnosed glaucoma patients report blurred vision, difficulty adapting between light and dark, trouble seeing in the dark, and problems with bright lights, and that visual field testing was only modestly correlated with patient complaints.<sup id="cite_ref-mills4_4-1" class="reference"><a href="#cite_note-mills4-4">&#91;4&#93;</a></sup> These findings underscore the importance of screening glaucoma patients for visual disability outside of clinical testing.  Vision related quality of life may be a more useful patient-centered outcome measurement, as well as something that can be targeted through LVS.<sup id="cite_ref-mills4_4-2" class="reference"><a href="#cite_note-mills4-4">&#91;4&#93;</a></sup>
</p><p>The most common glaucoma patient complaints are difficulties with mobility, reading, and driving.<sup id="cite_ref-pabon5_5-1" class="reference"><a href="#cite_note-pabon5-5">&#91;5&#93;</a></sup>  When glaucoma patients were surveyed about their mobility, a review found 49% of patients have difficulty with steps, 42% with shopping, and 36% with crossing the road.<sup id="cite_ref-ramulu6_6-1" class="reference"><a href="#cite_note-ramulu6-6">&#91;6&#93;</a></sup>  This difficulty was correlated with a significant increase in falls, entry into assisted living, restricted physical activity, and a decreased quality of life, leading to an overall increase in morbidity and mortality.<sup id="cite_ref-ramulu6_6-2" class="reference"><a href="#cite_note-ramulu6-6">&#91;6&#93;</a></sup> For glaucoma patients surveyed about reading 40% of patients endorse general difficulty.<sup id="cite_ref-ramulu6_6-3" class="reference"><a href="#cite_note-ramulu6-6">&#91;6&#93;</a></sup>  Research examining the extent and cause of the reading deficit found reading difficulty in glaucoma patients even with retained acuity, difficulty following a line or moving to the next line, difficulty with small print or low contrast, and decreased reading speeds to the point of reading impairment (less than 80 words per minute) in sustained silent reading.<sup id="cite_ref-viswanathan12_13-0" class="reference"><a href="#cite_note-viswanathan12-13">&#91;13&#93;</a></sup><sup id="cite_ref-altangerel13_14-0" class="reference"><a href="#cite_note-altangerel13-14">&#91;14&#93;</a></sup><sup id="cite_ref-ramulu14_15-0" class="reference"><a href="#cite_note-ramulu14-15">&#91;15&#93;</a></sup>  Finally, glaucoma patients surveyed about driving reported increased perceived difficulty with driving, particularly at night, with mixed data on increased risk of collisions and resulting morbidity and mortality.  However, glaucoma patients are three times more likely to stop driving due to their perceived deficits, which is associated with higher rates of entry into assisted living, lower quality of life, and depression. The resulting loss of function in all three categories of mobility, reading, and driving is correlated with increased rates of depression and anxiety.<sup id="cite_ref-pabon5_5-2" class="reference"><a href="#cite_note-pabon5-5">&#91;5&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Evaluation_of_Low_Vision_in_Glaucoma">Evaluation of Low Vision in Glaucoma</span></h1>
<h2><span class="mw-headline" id="History">History</span></h2>
<p>Screen for patient functional complaints, patient quality of life, and ability to perform ADLs.<sup id="cite_ref-american9_9-1" class="reference"><a href="#cite_note-american9-9">&#91;9&#93;</a></sup>
</p>
<ul><li>Activities of Daily Vision Scale (ADVS)</li>
<li>National Eye Institute Visual Functioning Questionnaire (NEI-VFQ)</li>
<li>Visual Function Index (VF-14)</li>
<li>Visual Activities Questionnaire (VAQ)</li>
<li>Glaucoma Quality of Life (GQL-15)</li></ul>
<h2><span class="mw-headline" id="Visual_Acuity">Visual Acuity</span></h2>
<p>Test with high contrast charts and bright lighting.  Encourage the patient to shift their gaze or move their head to find the optimum fixation point for best vision.<sup id="cite_ref-pabon5_5-3" class="reference"><a href="#cite_note-pabon5-5">&#91;5&#93;</a></sup>
</p>
<ul><li>Projection charts: Not appropriate due to low contrast and presentation in a dark room</li>
<li>Sloan chart: Use brightly lit at 10 ft</li>
<li>Early Treatment <a href="/Diabetic_Retinopathy" title="Diabetic Retinopathy">Diabetic Retinopathy</a> Study (ETDRS) chart: For visual acuity &lt;20/100</li>
<li>Designs for Vision Distance Test Chart for the Partially Sighted: For severe acuity loss</li></ul>
<h2><span class="mw-headline" id="Near_Acuities">Near Acuities</span></h2>
<p>Carefully evaluate due to common patient complaints regarding reading.<sup id="cite_ref-robison7_7-1" class="reference"><a href="#cite_note-robison7-7">&#91;7&#93;</a></sup>
</p>
<ul><li>Bailey-Lovie Near Reading Card: Tests whole word reading acuity, more useful in evaluating patients for reading aids than single letter acuities</li></ul>
<h2><span class="mw-headline" id="Visual_Field">Visual Field</span></h2>
<p>Evaluate what remaining field is available for rehabilitation.<sup id="cite_ref-robison7_7-2" class="reference"><a href="#cite_note-robison7-7">&#91;7&#93;</a></sup>
</p>
<ul><li>Goldmann perimeter: Large stimuli for easier assessment</li>
<li>Humphrey automated 10-2 field: For remaining central field in advanced glaucoma</li></ul>
<h2><span class="mw-headline" id="Contrast_Sensitivity">Contrast Sensitivity</span></h2>
<p>Important for resolving objects in daily visual tasks, such as recognizing a face, distinguishing between pills, or resolving where steps begin and end<sup id="cite_ref-robison7_7-3" class="reference"><a href="#cite_note-robison7-7">&#91;7&#93;</a></sup>
</p>
<ul><li>Pelli-Robson Contrast Sensitivity Chart: One size letters with decreasing contrast, patients must be able to see 40M-sized letters</li>
<li>VISTECH contrast test: Sine-wave/bar patterns for vision less than 20/40</li></ul>
<h2><span class="mw-headline" id="Observation_of_Patient">Observation of Patient</span></h2>
<p>Observe the patient performing visual tasks, e.g., reading, writing, walking, navigating steps.<sup id="cite_ref-pabon5_5-4" class="reference"><a href="#cite_note-pabon5-5">&#91;5&#93;</a></sup>
</p>
<ul><li>Quality of continuous reading, reading speeds, print size, errors in certain field locations</li>
<li>Speed of walking, head swing and room scanning, missed objects/bumping into items</li></ul>
<h1><span class="mw-headline" id="Management_of_Glaucoma_Patients_with_Low_Vision">Management of Glaucoma Patients with Low Vision</span></h1>
<p>The goal of LVS is to increase the patient’s ability to maximize function with their remaining vision.<sup id="cite_ref-american9_9-2" class="reference"><a href="#cite_note-american9-9">&#91;9&#93;</a></sup>
</p>
<h2><span id="Near_magnification[7]"></span><span class="mw-headline" id="Near_magnification.5B7.5D">Near magnification<sup id="cite_ref-robison7_7-4" class="reference"><a href="#cite_note-robison7-7">&#91;7&#93;</a></sup></span></h2>
<ul><li>Handheld/stand/electronic magnifiers: Electronic magnifiers are the gold standard in LVS due to variable magnification, high contrast, and black/white reversible polarity</li>
<li>Computer Screen magnification programs, screen readers</li></ul>
<h2><span class="mw-headline" id="Field_Enhancement">Field Enhancement</span></h2>
<ul><li>Scanning: Head swings, eye sweeps, slower approach speed. Helps patients to increase their awareness of the areas that need to be processed and develop a systematic plan for search patterns</li>
<li>Field Expanders: Minifiers, reverse telescopes, or prisms to reduce the entire field into the central field or transfer the peripheral field onto the central field. Helps patients in static scenarios (spotting objects, viewing from a stable position), not for dynamic use (walking)</li></ul>
<h2><span class="mw-headline" id="Glare_control">Glare control</span></h2>
<ul><li>Discomfort glare: Causes discomfort and reduces visual task efficiency but not resolution</li>
<li>Manage by turning down lights, adjusting angle of incoming light, absorptive lenses</li>
<li>Disability glare: Reduces the resolution/ ability to identify visual stimulus</li>
<li>Manage with polarizing lenses, anti-reflective coatings, incandescent lighting</li></ul>
<h2><span class="mw-headline" id="ADL_Assistance">ADL Assistance</span></h2>
<ul><li>Referred retinal locus and eccentric fixation training for preserved, non-central vision</li>
<li>Room lighting: Even, without shadow, adequate for mobility and ADLs but without glare or reflections</li>
<li>For missing visual field: Typoscope, signature guide, place markers</li>
<li>Tactile aids: Dots, plasticized marking pens, bold line markers</li>
<li>Talking devices: Watches, clocks, calculators, phones</li>
<li>Orientation and mobility training</li></ul>
<h2><span class="mw-headline" id="Mental_Health_Impairments">Mental Health Impairments</span></h2>
<ul><li>Networking, social support system, team concept: Important for combating increased rates of depression and anxiety</li></ul>
<h1><span class="mw-headline" id="Treatment_Outcomes">Treatment Outcomes</span></h1>
<p>LVS treatment outcomes have been evaluated using clinical questionnaires in multiple studies prior to and after completion of 3 to 9 months of therapy.  A wide range of measures have been used, and many categories were found to be improved by a statistically significant amount from baseline following treatment including overall visual ability, reading, visual information processing, mobility, near tasks, social functioning, and emotional well-being.<sup id="cite_ref-goldstein15_16-0" class="reference"><a href="#cite_note-goldstein15-16">&#91;16&#93;</a></sup><sup id="cite_ref-lamoureux16_17-0" class="reference"><a href="#cite_note-lamoureux16-17">&#91;17&#93;</a></sup><sup id="cite_ref-patodia17_18-0" class="reference"><a href="#cite_note-patodia17-18">&#91;18&#93;</a></sup> The improvements in overall visual ability in particular showed clinically meaningful improvements in nearly half of the patients attending LVS.<sup id="cite_ref-goldstein15_16-1" class="reference"><a href="#cite_note-goldstein15-16">&#91;16&#93;</a></sup>  The magnitude of the improvement in all categories and across studies was characterized as moderate.<sup id="cite_ref-goldstein15_16-2" class="reference"><a href="#cite_note-goldstein15-16">&#91;16&#93;</a></sup><sup id="cite_ref-lamoureux16_17-1" class="reference"><a href="#cite_note-lamoureux16-17">&#91;17&#93;</a></sup>
</p><p>However, these data are for all patients utilizing LVS and the majority of LVS referrals are patients with central vision loss, such as in <a href="/Age-Related_Macular_Degeneration" title="Age-Related Macular Degeneration">age-related macular degeneration</a> (AMD).<sup id="cite_ref-kaleem18_19-0" class="reference"><a href="#cite_note-kaleem18-19">&#91;19&#93;</a></sup>  In one study evaluating the effect of LVS on glaucoma patients, those with best-corrected visual acuity (BCVA) between 20/70 and 20/400 in the better-seeing eye and a diagnosis of glaucoma were randomized to either low-vision examination and treatment or only low-vision examination.<sup id="cite_ref-patodia17_18-1" class="reference"><a href="#cite_note-patodia17-18">&#91;18&#93;</a></sup>  A significant improvement was found in reading ability and overall visual ability following LVS when compared to the control group.<sup id="cite_ref-patodia17_18-2" class="reference"><a href="#cite_note-patodia17-18">&#91;18&#93;</a></sup>
</p><p>The data for low vision in glaucoma patients is still developing.  It is clear that there is a large population of glaucoma patients, many of which have visual functional deficits that meet criteria for low vision.  In the setting of these irreversible deficits, patient disability can be targeted through low vision examination and services.  It is important to identify these patients, discuss strategies for improved functionality, and refer them to the appropriate LVS in a timely fashion. 
</p>
<h1><span class="mw-headline" id="Additional_Resources">Additional Resources</span></h1>
<ul><li>Turbert D, and Dan Gudgel John D Shepherd, Mary Lou Jackson, Linda M Lawrence, Terry L Schwartz. <a rel="nofollow" class="external text" href="https://www.aao.org/eye-health/diseases/low-vision-list">Low Vision</a>. American Academy of Ophthalmology. EyeSmart<sup>®</sup> Eye health. <a rel="nofollow" class="external free" href="https://www.aao.org/eye-health/diseases/low-vision-list">https://www.aao.org/eye-health/diseases/low-vision-list</a>. Accessed March 14, 2019.</li></ul>
<h1><span class="mw-headline" id="References">References</span></h1>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-tham1-1"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-tham1_1-0">1.0</a></sup> <sup><a href="#cite_ref-tham1_1-1">1.1</a></sup></span> <span class="reference-text">Tham, Yih-Chung, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121.11 (2014): 2081-2090.</span>
</li>
<li id="cite_note-cesareo2-2"><span class="mw-cite-backlink"><a href="#cite_ref-cesareo2_2-0">↑</a></span> <span class="reference-text">Cesareo, Massimo, et al. Visual disability and quality of life in glaucoma patients. Progress in Brain Research 221 (2015): 359-374.</span>
</li>
<li id="cite_note-medeiros3-3"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-medeiros3_3-0">3.0</a></sup> <sup><a href="#cite_ref-medeiros3_3-1">3.1</a></sup></span> <span class="reference-text">Medeiros, Felipe A., et al. Longitudinal changes in quality of life and rates of progressive visual field loss in glaucoma patients. Ophthalmology 122.2 (2015): 293-301.</span>
</li>
<li id="cite_note-mills4-4"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-mills4_4-0">4.0</a></sup> <sup><a href="#cite_ref-mills4_4-1">4.1</a></sup> <sup><a href="#cite_ref-mills4_4-2">4.2</a></sup></span> <span class="reference-text">Mills, Richard P., et al. Correlation of visual field with quality-of-life measures at diagnosis in the Collaborative Initial Glaucoma Treatment Study (CIGTS). Journal of Glaucoma 10.3 (2001): 192-198.</span>
</li>
<li id="cite_note-pabon5-5"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-pabon5_5-0">5.0</a></sup> <sup><a href="#cite_ref-pabon5_5-1">5.1</a></sup> <sup><a href="#cite_ref-pabon5_5-2">5.2</a></sup> <sup><a href="#cite_ref-pabon5_5-3">5.3</a></sup> <sup><a href="#cite_ref-pabon5_5-4">5.4</a></sup></span> <span class="reference-text">Pabon, Sheila, et al. Low Vision Therapy for Glaucoma Patients. Current Ophthalmology Reports (2017): 1-8.</span>
</li>
<li id="cite_note-ramulu6-6"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-ramulu6_6-0">6.0</a></sup> <sup><a href="#cite_ref-ramulu6_6-1">6.1</a></sup> <sup><a href="#cite_ref-ramulu6_6-2">6.2</a></sup> <sup><a href="#cite_ref-ramulu6_6-3">6.3</a></sup></span> <span class="reference-text">Ramulu, Pradeep. Glaucoma and disability: which tasks are affected, and at what stage of disease? Current Opinion in Ophthalmology 20.2 (2009): 92.</span>
</li>
<li id="cite_note-robison7-7"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-robison7_7-0">7.0</a></sup> <sup><a href="#cite_ref-robison7_7-1">7.1</a></sup> <sup><a href="#cite_ref-robison7_7-2">7.2</a></sup> <sup><a href="#cite_ref-robison7_7-3">7.3</a></sup> <sup><a href="#cite_ref-robison7_7-4">7.4</a></sup></span> <span class="reference-text">Robison, Scott. Advanced Glaucoma and Low Vision: Evaluation and Treatment. The Glaucoma Book. Springer New York, 2010. 351-381.</span>
</li>
<li id="cite_note-renieri8-8"><span class="mw-cite-backlink"><a href="#cite_ref-renieri8_8-0">↑</a></span> <span class="reference-text">Renieri, Giulia, et al. Changes in quality of life in visually impaired patients after low-vision rehabilitation. International Journal of Rehabilitation Research 36.1 (2013): 48-55.</span>
</li>
<li id="cite_note-american9-9"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-american9_9-0">9.0</a></sup> <sup><a href="#cite_ref-american9_9-1">9.1</a></sup> <sup><a href="#cite_ref-american9_9-2">9.2</a></sup></span> <span class="reference-text">American Academy of Ophthalmology Vision Rehabilitation Committee. Preferred Practice Pattern Guidelines. Vision Rehabilitation. San Francisco, CA: American Academy of Ophthalmology; 2013.</span>
</li>
<li id="cite_note-massof10-10"><span class="mw-cite-backlink"><a href="#cite_ref-massof10_10-0">↑</a></span> <span class="reference-text">Massof, Robert W. A model of the prevalence and incidence of low vision and blindness among adults in the US. Optometry &amp; Vision Science 79.1 (2002): 31-38.</span>
</li>
<li id="cite_note-hu11-11"><span class="mw-cite-backlink"><a href="#cite_ref-hu11_11-0">↑</a></span> <span class="reference-text">Hu, Cindy X., et al. What do patients with glaucoma see? Visual symptoms reported by patients with glaucoma. The American Journal of the Medical Sciences 348.5 (2014): 403-409.</span>
</li>
<li id="cite_note-12"><span class="mw-cite-backlink"><a href="#cite_ref-12">↑</a></span> <span class="reference-text">Kaleem MA, Rajjoub R, Schiefer C, et al. Characteristics of Glaucoma Patients Attending a Vision Rehabilitation Service. Ophthalmol Glaucoma. 2021;S2589-4196(21)00064-8.</span>
</li>
<li id="cite_note-viswanathan12-13"><span class="mw-cite-backlink"><a href="#cite_ref-viswanathan12_13-0">↑</a></span> <span class="reference-text">Viswanathan, Ananth C., et al. Severity and stability of glaucoma: patient perception compared with objective measurement. Archives of Ophthalmology 117.4 (1999): 450-454.</span>
</li>
<li id="cite_note-altangerel13-14"><span class="mw-cite-backlink"><a href="#cite_ref-altangerel13_14-0">↑</a></span> <span class="reference-text">Altangerel, Undraa, et al. Assessment of function related to vision (AFREV). Ophthalmic epidemiology 13.1 (2006): 67-80.</span>
</li>
<li id="cite_note-ramulu14-15"><span class="mw-cite-backlink"><a href="#cite_ref-ramulu14_15-0">↑</a></span> <span class="reference-text">Ramulu, Pradeep Y., et al. Difficulty with out-loud and silent reading in glaucoma. Investigative ophthalmology &amp; visual science 54.1 (2013): 666-672.</span>
</li>
<li id="cite_note-goldstein15-16"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-goldstein15_16-0">16.0</a></sup> <sup><a href="#cite_ref-goldstein15_16-1">16.1</a></sup> <sup><a href="#cite_ref-goldstein15_16-2">16.2</a></sup></span> <span class="reference-text">Goldstein, Judith E., et al. Clinically meaningful rehabilitation outcomes of low vision patients served by outpatient clinical centers. JAMA Ophthalmology 133.7 (2015): 762-769.</span>
</li>
<li id="cite_note-lamoureux16-17"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-lamoureux16_17-0">17.0</a></sup> <sup><a href="#cite_ref-lamoureux16_17-1">17.1</a></sup></span> <span class="reference-text">Lamoureux, Ecosse L., et al. The effectiveness of low-vision rehabilitation on participation in daily living and quality of life. Investigative Ophthalmology &amp; Visual Science 48.4 (2007): 1476-1482.</span>
</li>
<li id="cite_note-patodia17-18"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-patodia17_18-0">18.0</a></sup> <sup><a href="#cite_ref-patodia17_18-1">18.1</a></sup> <sup><a href="#cite_ref-patodia17_18-2">18.2</a></sup></span> <span class="reference-text">Patodia, Yogesh, et al. Clinical effectiveness of currently available low-vision devices in glaucoma patients with moderate-to-severe vision loss. Clinical Ophthalmology 11 (2017): 683.</span>
</li>
<li id="cite_note-kaleem18-19"><span class="mw-cite-backlink"><a href="#cite_ref-kaleem18_19-0">↑</a></span> <span class="reference-text">Kaleem, Mona A., et al. Referral to Low Vision Services for Glaucoma Patients: Referral Patterns and Characteristics of Those Who Refer. Journal of Glaucoma (2017).</span>
</li>
</ol></div>
<!-- 
NewPP limit report
Cached time: 20230306035150
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] In‐text annotation parser time: 0.001 seconds
CPU time usage: 0.178 seconds
Real time usage: 0.549 seconds
Preprocessor visited node count: 931/1000000
Post‐expand include size: 11634/2097152 bytes
Template argument size: 2478/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 0/100
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 11748/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  322.228      1 -total
 81.64%  263.075      1 Template:Article
 64.92%  209.184      8 Template:Infobox_section
 18.33%   59.062      1 Template:Infobox_disease
 18.23%   58.750      4 Template:UserLookup
  7.32%   23.586      1 Template:Get_active_contest
  5.41%   17.428      1 Template:Review_expired
  2.65%    8.544      2 Template:ICD10
  0.91%    2.919      2 Template:Infobox_end
  0.30%    0.956      2 Template:Infobox_begin
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Low_Vision_and_Vision_Rehabilitation_in_Glaucoma&amp;oldid=87680">https://eyewiki.org/w/index.php?title=Low_Vision_and_Vision_Rehabilitation_in_Glaucoma&amp;oldid=87680</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbpzysm39i">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Low_Vision_and_Vision_Rehabilitation_in_Glaucoma" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Low_Vision_and_Vision_Rehabilitation_in_Glaucoma" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Low_Vision_and_Vision_Rehabilitation_in_Glaucoma&amp;oldid=87680" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Low_Vision_and_Vision_Rehabilitation_in_Glaucoma&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on December 25, 2022, at 16:38.</div>
					<div>This page has been accessed 19,785 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,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" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0.001},"limitreport":{"cputime":"0.178","walltime":"0.549","ppvisitednodes":{"value":931,"limit":1000000},"postexpandincludesize":{"value":11634,"limit":2097152},"templateargumentsize":{"value":2478,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":0,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":11748,"limit":5000000},"timingprofile":["100.00%  322.228      1 -total"," 81.64%  263.075      1 Template:Article"," 64.92%  209.184      8 Template:Infobox_section"," 18.33%   59.062      1 Template:Infobox_disease"," 18.23%   58.750      4 Template:UserLookup","  7.32%   23.586      1 Template:Get_active_contest","  5.41%   17.428      1 Template:Review_expired","  2.65%    8.544      2 Template:ICD10","  0.91%    2.919      2 Template:Infobox_end","  0.30%    0.956      2 Template:Infobox_begin"]},"cachereport":{"timestamp":"20230306035150","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":874});});</script></body>
</html>